



Collaboration. Acceleration. Results.

NEWS RELEASE

January 8, 2010

For more information contact:

Carol Menaker – carol@myelinrepair.org

408-871-2410

Myelin Repair Foundation Names Mike Gresser, Ph.D. as Chief Scientific Officer

SARATOGA, Calif., Jan 08, 2010 -- Senior pharmaceutical industry veteran Dr. Mike Gresser has joined the Myelin Repair Foundation (MRF) as Chief Scientific Officer. Dr. Gresser's background in academic and industry research and development make him ideally suited to guide the MRF through the commercial development of its myelin repair discoveries.

"With our focus on a patient treatment outcome, it makes sense to have someone with Dr. Gresser's outstanding credentials as a "drug maker" leading our scientific effort at this time," says MRF President Scott Johnson. "I am delighted that our work has developed to the point where we could attract someone of Dr. Gresser's stature to join our team."

"The traditional gap between university-based science and commercial drug development has often meant that too much good science has not advanced toward potential patient treatments," says Dr. Gresser. "For a non-profit organization like the MRF to make this connection between academic scientists and pharma executives at this early stage of drug development isw [this early stag]fe of dru

Neuroscience Research as well as Inflammation Research. His team at Amgen worked on many molecular targets, introducing numerous small molecules, human antibodies, and other proteins into development. The work of Dr. Gresser and his team has led to three drugs coming to market. Dr. Gresser has been a member of the MRF's Drug Discovery Advisory Board since January 2009.

About the Myelin Repair Foundation

The Myelin Repair Foundation (MRF) - <http://www.myelinrepair.org> - is a Northern California-based, non-profit research organization focused on accelerating discovery and development of myelin repair therapeutics for multiple sclerosis.

###